2015

HAI Holds Workshops on EU Medicines Policy & Access to Medicines in Eastern Europe

HAI urges MEPs to support key amendments to TTIP resolution

The EU-US Trade Deal Could Leave Europeans Sick

HAI Launches Innovative Global Study to Improve Access to Insulin

2014

More work needed on new EMA conflicts of interest policy

EMA policy on clinical data publication a step ahead, but falls short of true potential

Abysmal decisions: Why the EC’s medicinal units shouldn’t be moved to DG Industry

Democracy violation: European Commission rejects citizens’ initiative to stop TTIP and CETA

School's IN for summer: HAI staff and interns inspired by Utrecht University's course on pharmaceutical policy analysis

Setting precedents: EMA must get clinical trial data policy right to truly act in public interest

HAI Europe calls on EMA's Management Board to stand for data transparency

Tamiflu review shows desperate need for full clinical trials data transparency

A new (and improved) model to regulate pharmaceutical promotion

Enhancing accountability in the medicines market: The Medicines Transparency Alliance

Bayer CEO's callous comments highlight failure of current biomedical innovation model

2013

When politicians go to the movies

2011

DG Trade State of Play reveals EU's ambitions for IP protection in FTAs

European drug regulator challenged over revolving door case involving former Director

Corporate funding linked to EU patient & consumer groups policy

2010

EMA reviews transparency criteria

HAI research on financial disclosure featured in article: European politicians' call for greater transparency

HAI Europe Statement: EMA talks the ‘conflicts of interest’ talk, but will it walk the walk?

Dutch Minister of Health supports HAI E's financial transparency recommendations to EMA

Report exposes how Big Pharma has hijacked EU-India trade deal

In perspective: EMA comments on HAI Europe's survey of financial disclosure

Impact of HAI Europe survey results: Two weeks on

HAI Europe survey reveals new data on financial transparency of patient and consumer organisations

HAI Europe recommendations for improved conflict of interest declarations at EMA

ISDB & MiEF criticize EMA over conflict of interest procedures

Review of conflict of interest policies in three European medicines regulation agencies